Basis of selection of first and second line highly active antiretroviral therapy for hiv/aids on genetic barrier to resistance: a literature review.

Current status and prospects of HIV treatment

Cihlar, Tomas
Fordyce, Marshall

June 2016

Current antiviral treatments can reduce HIV-associated morbidity, prolong survival, and prevent HIV ...

Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings

Wallis, Carole L.
Hughes, Michael D.
Ritz, Justin
Viana, Raquel
de Jesus, Carlos Silva
Saravanan, Shanmugam
van Schalkwyk, Marije
Mngqibisa, Rosie
Salata, Robert
Mugyenyi, Peter
Hogg, Evelyn
Hovind, Laura
Wieclaw, Linda
Gross, Robert
Godfrey, Catherine
Collier, Ann C.
Grinsztejn, Beatriz
Mellors, John W.

October 2020

CITATION: Wallis, C. L. et al. Diverse Human Immunodeficiency Virus–1 drug resistance profiles at sc...

Genetic consequences of antiviral therapy on HIV-1

Arenas, M

January 2015

A variety of enzyme inhibitors have been developed in combating HIV-1, however the fast evolutionary...

Basis of selection of first and second line highly active antiretroviral therapy for hiv/aids on genetic barrier to resistance: a literature review.

Christine Katusiime
Ponsiano Ocama
Andrew Kambugu

October 2016

The effectiveness of combination antiretroviral therapy (cART) continues to improve as treatment cho...

The development of Resistance to Antiretroviral Therapy for HIV Infected Individuals:a Systematic Review

de Sousa Cartaxo, Jesus
Nascimento Neto, Pedro JanuÃ¡rio
Lacerda Pinheiro, Sally FranÃ§a
Pereira de Lima, Marcos AntÃ´nio
da Silva Costa, Lucas
Pereira Alencar, Ãtila
Teixeira JÃºnior, Antonio Gilvan
Lima da Silva, ClÃ¡udio Gleidiston
Pereira Rodrigues, Nayara Luiza
Rolim Neto, Modesto Leite
Barbosa do Nascimento, VÃ¢nia

May 2015

Background: Antiretroviral treatment (ART) has reduced morbidity and mortality due to AIDS. However,...

The crosstalk between antiretrovirals pharmacology and HIV drug resistance

A. Giacomelli
L. Pezzati
S. Rusconi

January 2020

Introduction: The clinical development of antiretroviral drugs has been followed by a rapid and conc...

Drug-resistant human immunodefiency virus

Kozal, M.J.

January 2009

AbstractThe development of antiretroviral therapy has led to a major reduction in human immunodefici...

Genetic consequences of antiviral therapy on HIV-1

Arenas, M

January 2015

A variety of enzyme inhibitors have been developed in combating HIV-1, however the fast evolutionary...

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

Vijver, D.A. van de
Wensing, A.M.J.
Angarano, G.
Asjo, B.
Balotta, C.
Camacho, R.
Chaix, M.
Costagliola, D.
De Luca, A.
Derdelinckx, I.
Grossman, Z.
Hamouda, O.
Hatzakis, A.
Hemmer, R.
Hoepelman, A.I.M.
Horban, A.
Korn, K.
Kücherer, C.
Leitner, T.
Loveday, C.
MacRae, E.
Maljkovic, I.
Mendoza, C. de
Meyer, L.
Nielsen, C.
Op de Coul, E.L.M.
Omaasen, V.
Paraskevis, D.
Perrin, L.
Puchhammer-Stöckl, E.
Salminen, M.
Schmit, J.
Scheider, F.
Schuurman, R.
Soriano, V.
Stanczak, G.
Stanojevic, M.
Vandamme, A.
Laethem, K. van
Violin, M.
Wilde, K.
Yerly, S.
Zazzi, M.
Boucher, C.A.B.

March 2006

The genetic barrier, defined as the number of mutations required to overcome drug-selective pressur...

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

Vijver, D.A. van de
Wensing, A.M.J.
Angarano, G.
Asjo, B.
Balotta, C.
Camacho, R.
Chaix, M.
Costagliola, D.
De Luca, A.
Derdelinckx, I.
Grossman, Z.
Hamouda, O.
Hatzakis, A.
Hemmer, R.
Hoepelman, A.I.M.
Horban, A.
Korn, K.
Kücherer, C.
Leitner, T.
Loveday, C.
MacRae, E.
Maljkovic, I.
Mendoza, C. de
Meyer, L.
Nielsen, C.
Op de Coul, E.L.M.
Omaasen, V.
Paraskevis, D.
Perrin, L.
Puchhammer-Stöckl, E.
Salminen, M.
Schmit, J.
Scheider, F.
Schuurman, R.
Soriano, V.
Stanczak, G.
Stanojevic, M.
Vandamme, A.
Laethem, K. van
Violin, M.
Wilde, K.
Yerly, S.
Zazzi, M.
Boucher, C.A.B.

March 2006

The genetic barrier, defined as the number of mutations required to overcome drug-selective pressur...

Estimating HIV evolutionary pathways and the genetic barrier to drug resistance

Niko Beerenwinkel
A Martin Däumer
Tobias Sing
Thomas Lengauer
Joachim Selbig
Daniel Hoffmann
Rolf Kaiser

January 2005

Background. The evolution of drug-resistant viruses challenges the management of human immunodeficie...

Efficient Suppression of Minority Drug-Resistant HIV Type 1 (HIV-1) Variants Present at Primary HIV-1 Infection by Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Therapy

Metzner, Karin J.
Rauch, Pia
von Wyl, Viktor
Leemann, Christine
Grube, Christina
Kuster, Herbert
Böni, Jürg
Weber, Rainer
Günthard, Huldrych F.

August 2017

Background. Selection of preexisting minority variants of drug-resistant human immunodeficiency viru...

The Impact of HIV-1 Drug Escape on the Global Treatment Landscape

Collier, DA
Monit, C
Gupta, RK

July 2019

The rising prevalence of HIV drug resistance (HIVDR) could threaten gains made in combating the HIV ...

Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings

Hosseinipour, Mina C.
Gupta, Ravindra K.
Van Zyl, Gert
Eron, Joseph J.
Nachega, Jean B.

January 2013

Antiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching ...

Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings

Hosseinipour, Mina C.
Gupta, Ravindra K.
Van Zyl, Gert
Eron, Joseph J.
Nachega, Jean B.

January 2013

Antiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching ...

Current status and prospects of HIV treatment

Cihlar, Tomas
Fordyce, Marshall

June 2016

Current antiviral treatments can reduce HIV-associated morbidity, prolong survival, and prevent HIV ...

Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings

Wallis, Carole L.
Hughes, Michael D.
Ritz, Justin
Viana, Raquel
de Jesus, Carlos Silva
Saravanan, Shanmugam
van Schalkwyk, Marije
Mngqibisa, Rosie
Salata, Robert
Mugyenyi, Peter
Hogg, Evelyn
Hovind, Laura
Wieclaw, Linda
Gross, Robert
Godfrey, Catherine
Collier, Ann C.
Grinsztejn, Beatriz
Mellors, John W.

October 2020

CITATION: Wallis, C. L. et al. Diverse Human Immunodeficiency Virus–1 drug resistance profiles at sc...

Genetic consequences of antiviral therapy on HIV-1

Arenas, M

January 2015

A variety of enzyme inhibitors have been developed in combating HIV-1, however the fast evolutionary...

Basis of selection of first and second line highly active antiretroviral therapy for hiv/aids on genetic barrier to resistance: a literature review.

Christine Katusiime
Ponsiano Ocama
Andrew Kambugu

October 2016

The effectiveness of combination antiretroviral therapy (cART) continues to improve as treatment cho...

The development of Resistance to Antiretroviral Therapy for HIV Infected Individuals:a Systematic Review

de Sousa Cartaxo, Jesus
Nascimento Neto, Pedro JanuÃ¡rio
Lacerda Pinheiro, Sally FranÃ§a
Pereira de Lima, Marcos AntÃ´nio
da Silva Costa, Lucas
Pereira Alencar, Ãtila
Teixeira JÃºnior, Antonio Gilvan
Lima da Silva, ClÃ¡udio Gleidiston
Pereira Rodrigues, Nayara Luiza
Rolim Neto, Modesto Leite
Barbosa do Nascimento, VÃ¢nia

May 2015

Background: Antiretroviral treatment (ART) has reduced morbidity and mortality due to AIDS. However,...

The crosstalk between antiretrovirals pharmacology and HIV drug resistance

A. Giacomelli
L. Pezzati
S. Rusconi

January 2020

Introduction: The clinical development of antiretroviral drugs has been followed by a rapid and conc...

Drug-resistant human immunodefiency virus

Kozal, M.J.

January 2009

AbstractThe development of antiretroviral therapy has led to a major reduction in human immunodefici...

Genetic consequences of antiviral therapy on HIV-1

Arenas, M

January 2015

A variety of enzyme inhibitors have been developed in combating HIV-1, however the fast evolutionary...

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

Vijver, D.A. van de
Wensing, A.M.J.
Angarano, G.
Asjo, B.
Balotta, C.
Camacho, R.
Chaix, M.
Costagliola, D.
De Luca, A.
Derdelinckx, I.
Grossman, Z.
Hamouda, O.
Hatzakis, A.
Hemmer, R.
Hoepelman, A.I.M.
Horban, A.
Korn, K.
Kücherer, C.
Leitner, T.
Loveday, C.
MacRae, E.
Maljkovic, I.
Mendoza, C. de
Meyer, L.
Nielsen, C.
Op de Coul, E.L.M.
Omaasen, V.
Paraskevis, D.
Perrin, L.
Puchhammer-Stöckl, E.
Salminen, M.
Schmit, J.
Scheider, F.
Schuurman, R.
Soriano, V.
Stanczak, G.
Stanojevic, M.
Vandamme, A.
Laethem, K. van
Violin, M.
Wilde, K.
Yerly, S.
Zazzi, M.
Boucher, C.A.B.

March 2006

The genetic barrier, defined as the number of mutations required to overcome drug-selective pressur...

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

Vijver, D.A. van de
Wensing, A.M.J.
Angarano, G.
Asjo, B.
Balotta, C.
Camacho, R.
Chaix, M.
Costagliola, D.
De Luca, A.
Derdelinckx, I.
Grossman, Z.
Hamouda, O.
Hatzakis, A.
Hemmer, R.
Hoepelman, A.I.M.
Horban, A.
Korn, K.
Kücherer, C.
Leitner, T.
Loveday, C.
MacRae, E.
Maljkovic, I.
Mendoza, C. de
Meyer, L.
Nielsen, C.
Op de Coul, E.L.M.
Omaasen, V.
Paraskevis, D.
Perrin, L.
Puchhammer-Stöckl, E.
Salminen, M.
Schmit, J.
Scheider, F.
Schuurman, R.
Soriano, V.
Stanczak, G.
Stanojevic, M.
Vandamme, A.
Laethem, K. van
Violin, M.
Wilde, K.
Yerly, S.
Zazzi, M.
Boucher, C.A.B.

March 2006

The genetic barrier, defined as the number of mutations required to overcome drug-selective pressur...

Estimating HIV evolutionary pathways and the genetic barrier to drug resistance

Niko Beerenwinkel
A Martin Däumer
Tobias Sing
Thomas Lengauer
Joachim Selbig
Daniel Hoffmann
Rolf Kaiser

January 2005

Background. The evolution of drug-resistant viruses challenges the management of human immunodeficie...

Efficient Suppression of Minority Drug-Resistant HIV Type 1 (HIV-1) Variants Present at Primary HIV-1 Infection by Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Therapy

Metzner, Karin J.
Rauch, Pia
von Wyl, Viktor
Leemann, Christine
Grube, Christina
Kuster, Herbert
Böni, Jürg
Weber, Rainer
Günthard, Huldrych F.

August 2017

Background. Selection of preexisting minority variants of drug-resistant human immunodeficiency viru...

The Impact of HIV-1 Drug Escape on the Global Treatment Landscape

Collier, DA
Monit, C
Gupta, RK

July 2019

The rising prevalence of HIV drug resistance (HIVDR) could threaten gains made in combating the HIV ...

Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings

Hosseinipour, Mina C.
Gupta, Ravindra K.
Van Zyl, Gert
Eron, Joseph J.
Nachega, Jean B.

January 2013

Antiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching ...

Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings

Hosseinipour, Mina C.
Gupta, Ravindra K.
Van Zyl, Gert
Eron, Joseph J.
Nachega, Jean B.

January 2013

Antiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching ...

Current status and prospects of HIV treatment

Cihlar, Tomas
Fordyce, Marshall

June 2016

Current antiviral treatments can reduce HIV-associated morbidity, prolong survival, and prevent HIV ...

Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings

Wallis, Carole L.
Hughes, Michael D.
Ritz, Justin
Viana, Raquel
de Jesus, Carlos Silva
Saravanan, Shanmugam
van Schalkwyk, Marije
Mngqibisa, Rosie
Salata, Robert
Mugyenyi, Peter
Hogg, Evelyn
Hovind, Laura
Wieclaw, Linda
Gross, Robert
Godfrey, Catherine
Collier, Ann C.
Grinsztejn, Beatriz
Mellors, John W.

October 2020

CITATION: Wallis, C. L. et al. Diverse Human Immunodeficiency Virus–1 drug resistance profiles at sc...

Genetic consequences of antiviral therapy on HIV-1

Arenas, M

January 2015

A variety of enzyme inhibitors have been developed in combating HIV-1, however the fast evolutionary...

Basis of selection of first and second line highly active antiretroviral therapy for hiv/aids on genetic barrier to resistance: a literature review.

Abstract

Extracted data

Basis of selection of first and second line highly active antiretroviral therapy for hiv/aids on genetic barrier to resistance: a literature review.

Abstract

Extracted data

Related items

Related items